<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04655495</url>
  </required_header>
  <id_info>
    <org_study_id>parere 89_2019</org_study_id>
    <nct_id>NCT04655495</nct_id>
  </id_info>
  <brief_title>Impact of a Low-FODMAP Gluten-free Diet on Gut Microbiota and Circulating miRNAs in Celiac Disease Patients</brief_title>
  <acronym>FODMAP2019</acronym>
  <official_title>Impact of a Low-FODMAP Gluten-free Diet on Gut Microbiota and Circulating miRNAs in Different Phenotypes of Celiac Disease Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      15 patients with refractory celiac disease (RCD) and 15 patients with CD responsive to the&#xD;
      GFD between the ages of 21 and 60 will be enrolled. The aim of the research will be: 1) to&#xD;
      characterize the intestinal, blood and duodenal microbiota, then to evaluate both the&#xD;
      taxonomy of the identified bacteria and their relative abundance 2) to analyse the profile of&#xD;
      miRNAs from biopsy and fibroblasts isolated in the first duodenal portion, highlighting any&#xD;
      basal deregulation and, for fibroblasts, after treatment with the 33-mer immunogenic peptide&#xD;
      3) quantify and know the composition of the fecal microbiota in celiac patients with&#xD;
      persistent symptoms and in refractory celiac patients before (T0) and after (T28) treatment&#xD;
      with a low-FODMAP diet. The aim of the study is to observe a diversification of the&#xD;
      microbiota pattern of refractory patients vs. normoresponsive celiac patients and to observe&#xD;
      a deregulation in the expression of miRNAs, both basally on biopsies and after treatment with&#xD;
      the immunogenic peptide in primary fibroblast cultures.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Celiac disease (CD) is a chronic, autoimmune, multisystemic disorder caused by ingestion of&#xD;
      gluten contained in wheat. A chronic gluten-free diet (GFD) is the only therapy for CD,&#xD;
      however a small subgroup of patients is refractory to a GFD, in fact the pathology does not&#xD;
      regress even with a strict diet. The microbiota plays a fundamental role in the CD, in fact,&#xD;
      especially intestinal homeostasis requires balanced interactions between the microbiota, food&#xD;
      antigens and the host. It is widely recognized that intestinal microbiota plays a role in the&#xD;
      initiation and progression of intestinal inflammation in numerous chronic conditions, but&#xD;
      recent studies have shown that even the blood microbiota plays a fundamental role in&#xD;
      autoimmune diseases. Also microRNAs (miRNAs), RNA sequences of 20-22 non-coding nucleotides&#xD;
      that post-transcriptionally regulate gene expression, are molecules of interest in many&#xD;
      common diseases and therefore also in CD. Fermentable, Oligo-, Di-, Mono-saccharides And&#xD;
      Polyol (FODMAP) are short-chain carbohydrates with poor absorption in the small intestine&#xD;
      which increases gas production and intestinal osmolarity, which can trigger gastrointestinal&#xD;
      symptoms in sensitive individuals. A diet low in FODMAPs is a new dietary option for the&#xD;
      treatment of persistent gastrointestinal symptoms in celiac patients. Evaluating the effect&#xD;
      of this type of diet on intestinal microbiota changes and miRNA expression in celiac patients&#xD;
      with persistent gastroenterological symptoms and in patients with refractory celiac disease&#xD;
      represents an opportunity to understand how this dietary modification could contribute to the&#xD;
      development of this disease.&#xD;
&#xD;
      15 patients with refractory celiac disease (RCD) and 15 patients with CD responsive to the&#xD;
      GFD between the ages of 21 and 60 will be enrolled. The aim of the research will be: 1) to&#xD;
      characterize the intestinal, blood and duodenal microbiota, then to evaluate both the&#xD;
      taxonomy of the identified bacteria and their relative abundance 2) to analyse the profile of&#xD;
      miRNAs from biopsy and fibroblasts isolated in the first duodenal portion, highlighting any&#xD;
      basal deregulation and, for fibroblasts, after treatment with the 33-mer immunogenic peptide&#xD;
      3) quantify and know the composition of the fecal microbiota in celiac patients with&#xD;
      persistent symptoms and in refractory celiac patients before (T0) and after (T28) treatment&#xD;
      with a low-FODMAP diet. The aim of the study is to observe a diversification of the&#xD;
      microbiota pattern of refractory patients vs. normoresponsive celiac patients and to observe&#xD;
      a deregulation in the expression of miRNAs, both basally on biopsies and after treatment with&#xD;
      the immunogenic peptide in primary fibroblast cultures.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 6, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Microbiota alpha and beta diversity</measure>
    <time_frame>28 days</time_frame>
    <description>Evaluate both the biodiversity and the relative abundance of haematic, intestinal and duodenal bacteria in the refractory celiac population of type I and II compared to normoresponsive celiac patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>miRNAs</measure>
    <time_frame>28 days</time_frame>
    <description>Evaluate the regulation of duodenal miRNAs in RCD patients and compare them with the miRNAs expressed in normoresponsive patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IBS symptoms</measure>
    <time_frame>28 days</time_frame>
    <description>Improvement of VAS values of IBS symptoms in patients undergoing a balanced Gluten Free/low FODMAPs diet compared to patients undergoing only a balanced. Evaluated IBS symptoms are: abdominal pain, bloating, satisfaction with stool consistency, epigastric pain, postprandial fullness, early satiety.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36</measure>
    <time_frame>28 days</time_frame>
    <description>Improvement of quality of life assessed through SF-36 questionnaire (eight scale scores) in patients undergoing a balanced Gluten Free/low FODMAPs diet compared to patients undergoing only a balanced gluten free diet.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SCL 90</measure>
    <time_frame>28 days</time_frame>
    <description>Improvement of psychological problems and symptoms of psychopathology through the symptom checklist 90 R (SCL 90 R) in patients undergoing a balanced Gluten Free/low FODMAPs diet compared to patients undergoing only a balanced gluten free diet</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dietary intake</measure>
    <time_frame>28 days</time_frame>
    <description>Evaluation of the dietary intake in micro and macro-nutrients before and after following the assigned diet through questionnaire.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Celiac Disease</condition>
  <arm_group>
    <arm_group_label>Low FODMAPs /balanced gluten free diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dietary Supplement: Balanced low FODMAPs /gluten free diet. An expert in nutrition will give a balanced gluten free diet to patients, low in FODMAPs foods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Balanced gluten free diet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Balanced gluten free diet. An expert in nutrition will give a balanced gluten free diet to patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Low FODMAPs /balanced gluten free diet</intervention_name>
    <description>Dietary Supplement: Balanced low FODMAPs /gluten free diet</description>
    <arm_group_label>Balanced gluten free diet</arm_group_label>
    <arm_group_label>Low FODMAPs /balanced gluten free diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients on a proper gluten-free diet (assessing adherence to the gluten-free diet&#xD;
             using the Celiac Dietary Adherence Test (CDAT)&#xD;
&#xD;
          -  celiac subjects diagnosed through a positive serological test of anti-endomysium&#xD;
             antibodies (EMA) and tissue transglutaminase antibodies (TTG) evaluated through a&#xD;
             histological abnormality in duodenal biopsies in accordance with Marsh's modified&#xD;
             classification&#xD;
&#xD;
          -  refractory celiac disease (CD)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding&#xD;
&#xD;
          -  Subjects who follow special diets: vegetarianism, veganism&#xD;
&#xD;
          -  Subjects with psychiatric disorders, diabetes mellitus, autoimmune systemic diseases,&#xD;
             previous anaphylactic episodes, systemic disorders&#xD;
&#xD;
          -  individual intolerance to disaccharides evaluated through the expired hydrogen test&#xD;
             (lactose and fructose)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Leda Roncoroni, MS, PhD</last_name>
    <phone>+390255033384</phone>
    <email>leda.roncoroni@unimi.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Leda Roncoroni</name>
      <address>
        <city>Milan</city>
        <zip>20100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Luca Elli, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Leda Roncoroni, MS, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alice Scricciolo, MS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vincenza Lombardo, BS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>https://doi.org/10.1016/j.humic.2018.12.001</url>
    <description>Results Reference</description>
  </link>
  <results_reference>
    <citation>Marasco G, Di Biase AR, Schiumerini R, Eusebi LH, Iughetti L, Ravaioli F, Scaioli E, Colecchia A, Festi D. Gut Microbiota and Celiac Disease. Dig Dis Sci. 2016 Jun;61(6):1461-72. doi: 10.1007/s10620-015-4020-2. Epub 2016 Jan 2. Review.</citation>
    <PMID>26725064</PMID>
  </results_reference>
  <results_reference>
    <citation>Wacklin P, Laurikka P, Lindfors K, Collin P, Salmi T, Lähdeaho ML, Saavalainen P, Mäki M, Mättö J, Kurppa K, Kaukinen K. Altered duodenal microbiota composition in celiac disease patients suffering from persistent symptoms on a long-term gluten-free diet. Am J Gastroenterol. 2014 Dec;109(12):1933-41. doi: 10.1038/ajg.2014.355. Epub 2014 Nov 18.</citation>
    <PMID>25403367</PMID>
  </results_reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 17, 2020</study_first_submitted>
  <study_first_submitted_qc>November 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2020</study_first_posted>
  <last_update_submitted>February 9, 2021</last_update_submitted>
  <last_update_submitted_qc>February 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FODMAPs diet</keyword>
  <keyword>celiac disease</keyword>
  <keyword>microbiota</keyword>
  <keyword>miRNA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celiac Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

